Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): subgroup analysis of 2 randomized phase 3 studies. (October 2018) - Cristofanilli, Massimo; Harbeck, Nadia; Rugo, Hope; Castrellon, Aurelio; Joy, Anyl A.; Verma, Sunil; Im, Seock-Ah; Iyer, Shrividya; Puyana, Kathy; Gauthier, Eric; Huang, Xin; Bartlett, Cynthia Huang; et al.